Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine

References

• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256. DOI:10.1016/j.neuron.2011.09.011.
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–268. DOI:10.1016/j.neuron.2011.09.010.
   PubMed Web of Science ®Google Scholar
• Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195–200. DOI:10.1038/nature13124.
   PubMed Web of Science ®Google Scholar
• Rossi S, Serrano A, Gerbino V, et al. Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS. J Cell Sci. 2015;128(9):1787–1799. DOI:10.1242/jcs.165332.
   PubMed Web of Science ®Google Scholar
• Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129–133. DOI:10.1038/nature14974.
   PubMed Web of Science ®Google Scholar
• Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56–61. DOI:10.1038/nature14973.
   PubMed Web of Science ®Google Scholar
• Zhang K, Daigle JG, Cunningham KM, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(4):958–71 e17. DOI:10.1016/j.cell.2018.03.025.
   PubMed Web of Science ®Google Scholar
• Beck M, Forster F, Ecke M, et al. Nuclear pore complex structure and dynamics revealed by cryoelectron tomography. Science. 2004;306(5700):1387–1390. DOI:10.1126/science.1104808.
   PubMed Web of Science ®Google Scholar
• Amlacher S, Sarges P, Flemming D, et al. Insight into structure and assembly of the nuclear pore complex by utilizing the genome of a eukaryotic thermophile. Cell. 2011;146(2):277–289. DOI:10.1016/j.cell.2011.06.039.
   PubMed Web of Science ®Google Scholar
• Hoelz A, Glavy JS, Beck M. Toward the atomic structure of the nuclear pore complex: when top down meets bottom up. Nat Struct Mol Biol. 2016;23(7):624–630.
   PubMed Web of Science ®Google Scholar
• Li N, Lagier-Tourenne C. Nuclear pores: the gate to neurodegeneration. Nat Neurosci. 2018;21(2):156–158.
   PubMed Web of Science ®Google Scholar
• Hayes LR, Duan L, Bowen K, et al. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9. DOI:10.7554/eLife.51685
   Web of Science ®Google Scholar
• Coyne AN, Zaepfel BL, Hayes L, et al. G4C2 repeat RNA initiates a POM121-mediated reduction in specific nucleoporins in C9orf72 ALS/FTD. Neuron. 2020;107(6):1124–40 e11. DOI:10.1016/j.neuron.2020.06.027.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bravo V, Pippa R, Song WM, et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell. 2018;174(5):1200–15 e20. DOI:10.1016/j.cell.2018.07.015.
   PubMed Web of Science ®Google Scholar
• Wang J, Saul A, Roon P, et al. Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration. Proc Natl Acad Sci U S A. 2016;113(26):E3764–72.
   PubMed Web of Science ®Google Scholar
• Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science. 1988;240(4849):219–221.
   PubMed Web of Science ®Google Scholar
• Graybiel AM, Besson MJ, Weber E. Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat. J Neurosci. 1989;9(1):326–338.
   PubMed Web of Science ®Google Scholar
• Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin Neurosci. 1989;1(1):7–15.
   PubMedGoogle Scholar
• Smith SB, Wang J, Cui X, et al. Sigma 1 receptor: a novel therapeutic target in retinal disease. Prog Retin Eye Res. 2018;67:130–149.
   PubMed Web of Science ®Google Scholar
• Sambo DO, Lin M, Owens A, et al. The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission. Nat Commun. 2017;8(1):2228. DOI:10.1038/s41467-017-02087-x.
   PubMedGoogle Scholar
• Mavlyutov TA, Epstein ML, Andersen KA, et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167(2):247–255.
   PubMed Web of Science ®Google Scholar
• Francardo V, Bez F, Wieloch T, et al. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137(Pt 7):1998–2014.
   PubMedGoogle Scholar
• Schmidt HR, Zheng S, Gurpinar E, et al. Crystal structure of the human sigma1 receptor. Nature. 2016;532(7600):527–530.
   PubMed Web of Science ®Google Scholar
• Crouzier L, Couly S, Roques C, et al. Sigma-1 (sigma1) receptor activity is necessary for physiological brain plasticity in mice. Eur Neuropsychopharmacol. 2020;39:29–45.
   PubMed Web of Science ®Google Scholar
• Rennekamp AJ, Huang XP, Wang Y, et al. sigma1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol. 2016;12(7):552–558. DOI:10.1038/nchembio.2089.
   PubMed Web of Science ®Google Scholar
• Fontanilla D, Johannessen M, Hajipour AR, et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934–937.
   PubMed Web of Science ®Google Scholar
• Zhemkov V, Ditlev JA, Lee WR, et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains. Elife. 2021;10. DOI:10.7554/eLife.65192.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131(3):596–610.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein M, Guo LW. Subcellular localization of the sigma-1 receptor in retinal neurons - an electron microscopy study. Sci Rep. 2015;5:10689.
   PubMed Web of Science ®Google Scholar
• Goguadze N, Zhuravliova E, Morin D, et al. Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress. Neurotox Res. 2019;35(1):1–18.
   PubMed Web of Science ®Google Scholar
• Su TP, Su TC, Nakamura Y, et al. The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci. 2016;37(4):262–278.
   PubMed Web of Science ®Google Scholar
• Lee PT, Lievens JC, Wang SM, et al. Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models. Nat Commun. 2020;11(1):5580. DOI:10.1038/s41467-020-19396-3.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Olivan S, Rando A, et al. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9(4):814–826.
   PubMed Web of Science ®Google Scholar
• Hyrskyluoto A, Pulli I, Tornqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-kappaB pathway. Cell Death Dis. 2013;4:e646.
   PubMed Web of Science ®Google Scholar
• Peviani M, Salvaneschi E, Bontempi L, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014;62:218–232.
   PubMed Web of Science ®Google Scholar
• Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16(4):373–389.
   PubMed Web of Science ®Google Scholar
• Monnet FP, de Costa BR, Bowen WD, et al. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Br J Pharmacol. 1996;119(1):65–72.
   PubMed Web of Science ®Google Scholar
• Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn Schmiedebergs Arch Pharmacol. 1995;351(3):252–260.
   PubMed Web of Science ®Google Scholar
• Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry. 2004;37 Suppl 3(S 3):S214–20.
   PubMedGoogle Scholar
• Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse. 2005;55(1):37–44.
   PubMed Web of Science ®Google Scholar
• Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165–176. DOI:10.1016/S1474-4422(18)30391-0.
   PubMed Web of Science ®Google Scholar
• McGarry A, Auinger P, Kieburtz K, et al. Additional safety and exploratory efficacy data at 48 and 60 months from open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9(2):173–184. DOI:10.3233/JHD-190393.
   PubMed Web of Science ®Google Scholar
• Tesei A, Cortesi M, Zamagni A, et al. Sigma receptors as endoplasmic reticulum stress “Gatekeepers” and their modulators as emerging new weapons in the fight against cancer. Front Pharmacol. 2018;9:711.
   PubMed Web of Science ®Google Scholar
• Tesei A, Cortesi M, Pignatta S, et al. Anti-tumor efficacy assessment of the sigma receptor pan modulator RC-106. A promising therapeutic tool for pancreatic cancer. Front Pharmacol. 2019;10:490.
   PubMed Web of Science ®Google Scholar
• Lagarde F, Beausoleil C, Belcher SM, et al. Non-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessment. Environ Health. 2015;14:13.
   PubMed Web of Science ®Google Scholar
• Hong WC, Yano H, Hiranita T, et al. The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats. J Biol Chem. 2017;292(27):11250–11261. DOI:10.1074/jbc.M116.774075.
   PubMed Web of Science ®Google Scholar
• Yano H, Bonifazi A, Xu M, et al. Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacology. 2018;133:264–275.
   PubMed Web of Science ®Google Scholar
• Zhemkov V, Geva M, Hayden MR, et al. Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082.
   PubMed Web of Science ®Google Scholar
• Johnston TH, Geva M, Steiner L, et al. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708–716. DOI:10.1002/mds.27565.
   PubMed Web of Science ®Google Scholar
• Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in huntington disease. Hum Mol Genet. 2016;25(18):3975–3987. DOI:10.1093/hmg/ddw238.
   PubMed Web of Science ®Google Scholar
• Garcia-Miralles M, Geva M, Tan JY, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2(23). DOI:10.1172/jci.insight.95665.
   PubMed Web of Science ®Google Scholar
• Ryskamp D, Wu L, Wu J, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489–504.
   PubMed Web of Science ®Google Scholar
• Francardo V, Geva M, Bez F, et al. Pridopidine induces functional neurorestoration Via the sigma-1 receptor in a mouse model of parkinson’s disease. Neurotherapeutics. 2019;16(2):465–479. DOI:10.1007/s13311-018-00699-9.
   PubMed Web of Science ®Google Scholar
• Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis. 2019;10(3):210. DOI:10.1038/s41419-019-1451-2.
   PubMedGoogle Scholar
• Eddings CR, Arbez N, Akimov S, et al. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019;129:118–129.
   PubMed Web of Science ®Google Scholar
• Naia L, Ly P, Mota SI, et al. The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in huntington disease models. Neurotherapeutics. 2021;18:1017–1038.
   PubMed Web of Science ®Google Scholar
• Shenkman M, Geva M, Gershoni-Emek N, et al. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. J Neurochem. 2021;158:467–481.
   PubMed Web of Science ®Google Scholar
• McGarry A, Leinonen M, Kieburtz K, et al. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. J Huntingtons Dis. 2020;9(4):371–380.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Noda T, Yoshimori T, et al. A protein conjugation system essential for autophagy. Nature. 1998;395(6700):395–398. DOI:10.1038/26506.
   PubMed Web of Science ®Google Scholar
• Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36(20):2931–2950.
   PubMed Web of Science ®Google Scholar
• Sardiello M, Palmieri M, Di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–477. DOI:10.1126/science.1174447.
   PubMed Web of Science ®Google Scholar
• Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429–1433. DOI:10.1126/science.1204592.
   PubMed Web of Science ®Google Scholar
• Palmieri M, Pal R, Nelvagal HR, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017;8:14338.
   PubMed Web of Science ®Google Scholar
• Li L, Friedrichsen HJ, Andrews S, et al. A TFEB nuclear export signal integrates amino acid supply and glucose availability. Nat Commun. 2018;9(1):2685. DOI:10.1038/s41467-018-04849-7.
   PubMed Web of Science ®Google Scholar
• Cunningham KM, Maulding K, Ruan K, et al. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020;9. DOI:10.7554/eLife.59419.
   Web of Science ®Google Scholar
• Perera RM, Stoykova S, Nicolay BN, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015;524(7565):361–365. DOI:10.1038/nature14587.
   PubMed Web of Science ®Google Scholar
• Dreser A, Vollrath JT, Sechi A, et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24(10):1655–1671. DOI:10.1038/cdd.2017.88.
   PubMed Web of Science ®Google Scholar
• Vollrath JT, Sechi A, Dreser A, et al. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis. 2014;5:e1290.
   PubMed Web of Science ®Google Scholar
• Christ MG, Huesmann H, Nagel H, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity In Vitro and In Vivo. Cells. 2019;8(3):211.
   PubMed Web of Science ®Google Scholar
• Coyne AN, Baskerville V, Zaepfel BL, et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13(604). DOI:10.1126/scitranslmed.abe1923.
   Web of Science ®Google Scholar
• Montilla-Garcia A, Perazzoli G, Tejada MA, et al. Modality-specific peripheral antinociceptive effects of mu-opioid agonists on heat and mechanical stimuli: contribution of sigma-1 receptors. Neuropharmacology. 2018;135:328–342.
   PubMed Web of Science ®Google Scholar
• Tanida I, Ueno T, Kominami E. LC3 and Autophagy. Methods Mol Biol. 2008;445:77–88.
   PubMedGoogle Scholar
• Qi W, Yan L, Liu Y, et al. Simvastatin aggravates impaired autophagic flux in NSC34-hSOD1G93A cells through inhibition of geranylgeranyl pyrophosphate synthesis. Neuroscience. 2019;409:130–141.
   PubMed Web of Science ®Google Scholar
• Puertollano R, Ferguson SM, Brugarolas J, et al. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11). DOI:10.15252/embj.201798804
   PubMed Web of Science ®Google Scholar
• Li C, Wang X, Li X, et al. Proteasome inhibition activates autophagy-lysosome pathway associated with TFEB dephosphorylation and nuclear translocation. Front Cell Dev Biol. 2019;7:170.
   PubMed Web of Science ®Google Scholar
• Chu UB, Ramachandran S, Hajipour AR, et al. Photoaffinity labeling of the sigma-1 receptor with N-[3-(4-nitrophenyl)propyl]-N-dodecylamine: evidence of receptor dimers. Biochemistry. 2013;52(5):859–868.
   PubMed Web of Science ®Google Scholar
• Gromek KA, Suchy FP, Meddaugh HR, et al. The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J Biol Chem. 2014;289(29):20333–20344. DOI:10.1074/jbc.M113.537993.
   PubMed Web of Science ®Google Scholar
• Carlsson SR, Roth J, Piller F, et al. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan. J Biol Chem. 1988;263(35):18911–18919.
   PubMed Web of Science ®Google Scholar
• Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913–919.
   PubMed Web of Science ®Google Scholar
• Mitra R, Gadkari MBA VV, van Mierlo Cpm, et al. Mechanism of the small ATP-independent chaperone Spy is substrate specific. Nat Commun. 2021;12(1):851.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Dryanovski DI, Kimura Y, et al. Cocaine-induced endocannabinoid signaling mediated by sigma-1 receptors and extracellular vesicle secretion. Elife. 2019;8:47209.
   Web of Science ®Google Scholar
• Ryskamp D, Wu J, Geva M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97(Pt A):46–59. DOI:10.1016/j.nbd.2016.10.006.
   PubMedGoogle Scholar
• Wang SM, Goguadze N, Kimura Y, et al. Genomic action of sigma-1 receptor chaperone relates to neuropathic pain. Mol Neurobiol. 2021;58(6):2523–2541. DOI:10.1007/s12035-020-02276-8.
   PubMed Web of Science ®Google Scholar